K
Kynos Therapeutics
First-in-class KMO inhibitors for treating inflammatory diseases
About Kynos Therapeutics
Kynos Therapeutics is a clinical-stage biopharmaceutical company that develops novel treatments for inflammatory diseases. The company was founded in 2020 as a spin-out from the University of Edinburgh by Professors Damian Mole and Scott Webster, based on over a decade of research into kynurenine 3-monooxygenase (KMO) biology. Jonathan Savidge has served as CEO since 2022.
The company focuses on developing inhibitors for the enzyme KMO, which plays a key role in regulating inflammation, immunity, and metabolism. By inhibiting KMO, the company's therapies aim to prevent excess tissue damage and immune system dysregulation. Its lead drug candidate, KNS366, is a highly selective, first-in-class KMO inhibitor. In a Phase I clinical trial, KNS366 was found to be safe, well-tolerated, and demonstrated potent inhibition of the KMO enzyme. The company's therapeutic pipeline targets critical illness post-surgery, conditions driven by inflammation, and certain cancers.
Kynos Therapeutics emerged from stealth in April 2022 with £9 million in financing, which included a £6.5 million equity round led by Epidarex Capital with participation from IP Group and Scottish Enterprise, and a £2.5 million grant from Innovate UK. The company was acquired by Dr. Falk Pharma GmbH in October 2024 and is now part of the Falk Group. Dr. Falk Pharma will continue the clinical development of KNS366, initially focusing on its application for acute pancreatitis, and integrating it into its own R&D pipeline for rare digestive and metabolic diseases.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2020
- Headquarters
- Edinburgh, United Kingdom
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 54.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, uk is8 life sciences, UKSU2010, Spinout, UKSU, Hard Tech, science-based, DT and LS, Biotech and Pharma, Biotechnology
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Oct 2024 | $0 | — | Dr. Falk Pharma | ↗ |
| GRANT✓Other financing | Apr 2022 | $3.3M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Kynos Therapeutics is 390 monthly website visits, up 1200% over the last three months. Kynos Therapeutics's team declined 66.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kynos Therapeutics in the Edinburgh ecosystem
The Kynos Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Epidarex Capital
Scottish Enterprise Growth Investments
IP Group
Other known investors2 additional known investors
Dr. Falk Pharma
University of Edinburgh
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kynos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kynos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








